^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

FL-101

i
Other names: FL-101
Associations
Company:
Leap Therap
Drug class:
IL-1β inhibitor
Associations
over2years
FL- 101 Study in Non-Metastatic MIBC (clinicaltrials.gov)
P1, N=0, Withdrawn, Flame Biosciences | Not yet recruiting --> Withdrawn
Trial withdrawal
|
CRP (C-reactive protein)
|
FL-101
over2years
Phase 0 Study of FL-101 in Non-Metastatic MIBC (clinicaltrials.gov)
P1, N=5, Not yet recruiting, Flame Biosciences
New P1 trial
|
CRP (C-reactive protein)
|
FL-101
almost3years
FL-101 in Surgically Resectable Non-Small Cell Lung Cancer (clinicaltrials.gov)
P2, N=0, Withdrawn, Flame Biosciences | N=90 --> 0 | Trial completion date: Feb 2023 --> Dec 2021 | Recruiting --> Withdrawn | Trial primary completion date: Oct 2022 --> Dec 2021
Clinical • Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
|
CRP (C-reactive protein)
|
Opdivo (nivolumab) • FL-101
3years
FL-101 in Surgically Resectable Non-Small Cell Lung Cancer (clinicaltrials.gov)
P2, N=90, Recruiting, Flame Biosciences | Not yet recruiting --> Recruiting
Clinical • Enrollment open
|
CRP (C-reactive protein)
|
Opdivo (nivolumab) • FL-101
over3years
New P2 trial
|
IL6 (Interleukin 6) • IL1B (Interleukin 1, beta) • CRP (C-reactive protein)
|
Opdivo (nivolumab) • FL-101
over3years
FL-101 in Surgically Resectable Non-Small Cell Lung Cancer (clinicaltrials.gov)
P2, N=90, Not yet recruiting, Flame Biosciences | N=180 --> 90 | Trial completion date: Apr 2025 --> Feb 2023 | Initiation date: Apr 2021 --> Jul 2021 | Trial primary completion date: Nov 2023 --> Oct 2022
Clinical • Enrollment change • Trial completion date • Trial initiation date • Trial primary completion date
|
CRP (C-reactive protein)
|
Opdivo (nivolumab) • FL-101
almost4years
Clinical • New P2 trial
|
CRP (C-reactive protein)
|
Opdivo (nivolumab) • FL-101